Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Oral Oncol. 2017 Jul 13;72:56–64. doi: 10.1016/j.oraloncology.2017.07.009

Fig. 3.

Fig. 3

Boxplots associating expression of smoking-dysregulated miRNAs to (A) clinical stages, (B) clinical T stage, (C) pathologic T stage and (D) pathologic N stage (Kruskal-Wallis, p < 0.05). In clinical stage analyses, patients with Stage I and II were classified as “Early Stage” and patients with Stage III and IV were classified as “Late Stage.”